证券代码：002432 证券简称：九安医疗 公告编号：2025-093 1、基本信息 机构名称：容诚会计师事务所（特殊普通合伙） 成立日期：1988年8月（2013年12月10日改制为特殊普通合伙企业） 组织形式：特殊普通合伙 天津九安医疗电子股份有限公司 关于续聘公司2025年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年 11月28日召开第六届董事会第二十九次会议及第六届监事会第二十三次会议，审 议通过了《关于续聘2025年度审计机构的议案》，拟续聘容诚会计师事务所（特 殊普通合伙）（以下简称"容诚"）为公司2025年度审计机构。本事项尚需提交 公司股东大会审议通过，现将有关事宜公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 近三年在执业中相关民事诉讼承担民事责任的情况： 2023年9月21日，北京金融法院就乐视网信息技术（北京）股份有限公司（ 以下简称乐视网）证券虚假陈述责任纠纷案[(2021)京74民初111号]作出判决，判 决华普天健咨询（北京） ...

天津九安医疗电子股份有限公司 独立董事提名人声明与承诺 提名人天津九安医疗电子股份有限公司董事会，现就提名毕晓方为天津九 安医疗电子股份有限公司第七届董事会独立董事候选人发表公开声明。被提名 人已书面同意作为天津九安医疗电子股份有限公司第七届董事会独立董事候 选人（参见该独立董事候选人声明）。本次提名是在充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼 职、有无重大失信等不良记录等情况 后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规范 性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要 求，具体声明并承诺如下事项： 一、被提名人已经通过天津九安医疗电子股份有限公司第六届董事会提名 委员会或者独立董事专门会议资格审查，提名人与被提名人不存在利害关系或 者其他可能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不 得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：_____________________________ ...

天津九安医疗电子股份有限公司（以下简称"公司"）于2025年11月28日召 开了第六届董事会第二十九次会议，会议决定于2025年12月15日召开公司2025 年第四次临时股东大会，本次股东大会采用现场投票及网络投票相结合的方式 进行。根据《公司章程》的规定，现将召开本次股东大会的有关事项公告如下： 一、召开会议的基本情况 1、股东会届次：2025年第四次临时股东大会 2、股东会的召集人：董事会 证券代码：002432 证券简称：九安医疗 公告编号：2025-094 3、公司第六届董事会第二十九次会议审议通过了《关于召开2025年第四次 临时股东大会的议案》，本次会议的召集、召开符合《中华人民共和国公司法》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第1 号——主板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及 《公司章程》的有关规定。 4、会议时间： 天津九安医疗电子股份有限公司 关于召开2025年第四次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 （3）公司聘请的律师； （4）根据相关法规应当出席股东 ...

天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年11月 25日以书面方式发出召开第六届监事会第二十三次会议的通知。会议于2025年11 月28日在公司会议室以现场表决方式召开。本次会议由公司监事会主席姚凯先生 主持，会议应参加的监事3名，实际参加的监事3名，会议的召集、召开与表决程 序符合《公司法》等法律法规及《公司章程》的规定。与会监事就会议议案进行 了审议及表决，通过了如下议案： 证券代码：002432 证券简称：九安医疗 公告编号：2025-095 天津九安医疗电子股份有限公司 第六届监事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 一、以3票同意、0票反对、0票弃权的表决结果，审议并通过了《关于续聘 2025年度审计机构的议案》 经过对容诚会计师事务所的专业能力、投资者保护能力、诚信状况及独立性 等方面进行充分审查，监事会认为其在执业过程中坚持独立审计原则，切实履行 了审计机构应尽的职责，在担任公司审计机构期间，勤勉尽责，公允合理地发表 了独立审计意见，具备胜任公司2025年度审计工作的专业资质与能力 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-090 天津九安医疗电子股份有限公司 第六届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"或"本公司"）于2025年11 月25日以通讯方式发出召开第六届董事会第二十九次会议的通知，会议于2025 年11月28日在公司会议室以现场和通讯表决相结合方式召开。本次会议由公司董 事长刘毅先生主持，会议应参加的董事6名，实际参加的董事6名，全体监事、公 司高级管理人员列席了会议，符合《公司法》及《公司章程》的规定。会议以投 票表决方式通过如下议案： 一、会议以6票同意、0票反对、0票弃权的表决结果，审议通过了《关于变 更注册资本、新增经营范围暨修订<公司章程>的议案》 公司因股票期权激励计划行权、回购股份注销事项，总股本数量发生变动。 截至本次董事会召开前一日，上述事项合计导致公司股份总数由486,140,322股变 更为464,919,840股，注册资本由486,140,322元人民币减少至464,919,840元人民币。 根 ...

Core Viewpoint - The article discusses the transition of Tianjin Hualai Technology Co., Ltd. (Hualai Technology) under the control of Liu Yi, who acquired the company at a significantly lower valuation compared to its previous worth, and highlights the company's financial performance and challenges in recent years [1][2][3]. Group 1: Company Background and Acquisition - Hualai Technology, founded in 2009, initially focused on website design before transitioning to smart home solutions under the leadership of Ye Ting, who became the controlling shareholder in 2015 [6][2]. - After Ye Ting's passing in September 2021, his shares were inherited by his 14-year-old son, Ye Jiaxin, who sold his stake to Liu Yi for approximately 1.17 billion yuan, valuing the company at 2.13 billion yuan, which is less than 30% of its previous valuation of 7.5 billion yuan [7][8][2]. Group 2: Financial Performance - Hualai Technology's cumulative net profit from 2022 to 2024 is projected to be around 2.36 billion yuan, surpassing the 2.13 billion yuan valuation at the time of acquisition [2][14]. - The company's revenue for 2022, 2023, and 2024 is reported as 8.82 billion yuan, 10.42 billion yuan, and 8.87 billion yuan, respectively, with net profits of 724.2 million yuan, 806.7 million yuan, and 825.2 million yuan [11][14]. - Despite the growth, the net profit has not returned to the peak of 917.1 million yuan achieved in 2021 [14]. Group 3: Client Dependency and Market Challenges - Hualai Technology's revenue is highly concentrated, with the top five clients contributing over 94% of total revenue during the reporting period, and Wyze, its largest client, accounting for 65.64%, 51.88%, and 48.47% of revenue from 2022 to 2024 [14][15]. - The company faced a revenue decline in 2024 due to strategic adjustments by major clients like Roku and Wyze, which affected procurement volumes [14][16]. Group 4: Strategic Partnerships and Future Outlook - Hualai Technology has been expanding its collaboration with Xiaomi, with revenue from Xiaomi-related business increasing from 10.07% in 2022 to 27.18% in 2024 [17]. - The company plans to raise funds through an IPO to invest in new smart home camera projects and a research center, with a total of 3.18 billion yuan allocated for these initiatives [18][19].

证券之星消息，九安医疗(002432)11月25日在投资者关系平台上答复投资者关心的问题。 九安医疗回复：尊敬的投资者您好。公司最新一期回购计划正在持续执行中。截至2025年11月21日，公 司已回购公司股份数约1022.87万股，支付的总金额约4.11亿元，回购尚未结束。关于后续进展情况，公 司会根据相关法律法规要求履行信息披露义务，谢谢。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 投资者提问：公司最近为什么停止回购，是因为价格太高了吗？ ...

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

Core Viewpoint - The issuance of the technology innovation bonds by Jiuan Medical was successful, achieving an AAA credit rating and a 1.83% issuance interest rate, with an initial issuance scale of 1.05 billion yuan, reflecting market trust and recognition of the company's development [1]. Group 1: Company Overview - Jiuan Medical is primarily known for producing common household health monitoring devices such as thermometers, blood pressure monitors, and pulse oximeters, but it has diversified into home medical health products, internet healthcare, and technology investment [1]. - The company plans to invest approximately 270 million yuan in research and development in 2024, focusing on projects like continuous glucose monitoring (CGM) and AIoT diabetes home assistance [1]. Group 2: Bond Issuance Process - The company faced initial challenges in the bond issuance process, particularly regarding credit rating, but successfully communicated with rating agencies to demonstrate asset quality and financial health, ultimately achieving an AAA rating [2][3]. - The technology innovation bonds are designed to meet the financing needs of technology companies, allowing funds to be used for R&D, direct investments, and fund contributions, thereby enhancing capital turnover efficiency and reducing overall financing costs [2]. Group 3: Market Context and Challenges - Jiuan Medical's financial indicators met the requirements for issuing technology innovation bonds, and its intellectual property, including FDA approval, was considered a significant asset in the evaluation process [3]. - The company expressed concerns about the bond market's unfamiliarity, including questions about the efficiency of the issuance process and the potential for successful fundraising, which were addressed in a policy briefing organized by the China Interbank Market Dealers Association [3]. Group 4: Industry Implications - The issuance of technology innovation bonds is expected to inject new momentum into Jiuan Medical and its associated funds, accelerating the transformation of quality projects and technological achievements [4]. - The current challenge for many technology innovation companies is their asset-light operating model, which often lacks public market ratings, limiting support from traditional financing channels [4][5].

Group 1 - Moonshot AI is set to complete a funding round that may raise its valuation to approximately $4 billion (28.4 billion RMB) with potential investment from firms like IDG Capital and Tencent [1] - The funding amount is expected to reach several hundred million dollars, and Moonshot AI may initiate an IPO next year [1] - The company recently launched KimiK2Thinking, its most advanced open-source thinking model, which excels in various benchmark tests, demonstrating state-of-the-art (SOTA) performance in areas such as autonomous web browsing and complex information reasoning [1] Group 2 - Jiuzan Medical has invested approximately $10 million in Moonshot AI through its wholly-owned subsidiary [2] - The company "What Worth Buying" has established collaborations with Moonshot AI and other general large model enterprises, integrating Kimi and other platforms to provide consumer information services [2]